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Evidence showing the ectopic re-expression of cell cycle-related proteins in specific vulnerable neuronal populations in Alzheimer disease led
us to formulate the hypothesis that neurodegeneration, like cancer, is a disease of inappropriate cell cycle control. To test this notion, we used
adenoviral-mediated expression of c-myc and ras oncogenes to drive postmitotic primary cortical neurons into the cell cycle. Cell cycle re-entry in
neurons was associated with increased DNA content, as determined using BrdU and DAPI, and the re-expression of cyclin B1, a marker for the
G2/M phase of the cell cycle. Importantly, we also found that cell cycle re-entry in primary neurons leads to tau phosphorylation and
conformational changes similar to that seen in Alzheimer disease. This study establishes that the cell cycle can be instigated in normally quiescent
neuronal cells and results in a phenotype that shares features of degenerative neurons in Alzheimer disease. As such, our neuronal cell model may
be extremely valuable for the development of novel therapeutic strategies.
© 2006 Elsevier B.V. All rights reserved.Keywords: Alzheimer disease; Cell cycle; Phosphorylation; Tau1. Introduction
Alzheimer disease (AD) is a chronic degenerative disorder
characterized by the intracellular accumulation of highly
phosphorylated tau within select neuronal populations [1,2].
While the mechanism(s) that lead to the accumulation of
phosphorylated tau are unresolved, an increasing body of
work suggests that cell cycle disturbances may play an early
role in disease pathogenesis [3–5]. In fact, highly phosphory-
lated tau is intimately linked to the cell cycle since a near
identical phosphorylation of tau also occurs when cells are
mitotically active and tau phosphorylation is driven by cyclin-
dependent kinases (CDKs) [6–10]. Of potential mechanistic
importance, a number of CDKs are ectopically re-expressed
in neurons in AD and such CDKs are known to phosphory-⁎ Corresponding author. Tel.: +1 216 368 3670; fax: +1 216 368 8964.
E-mail address: mark.smith@case.edu (M.A. Smith).
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doi:10.1016/j.bbadis.2006.09.010late tau in in vitro assays in a manner similar to that found in
AD in vivo [3,4,11–13]. Since cell cycle protein expression in
AD precedes the appearance of phosphorylated tau [14], a
possible cause–effect relationship is indicated. Although
neurons in the normal adult brain are generally quiescent and
in the G0 phase of the cell cycle, neurons vulnerable to
degeneration in AD appear to emerge from this postmitotic
state and are phenotypically suggestive of cells that have re-
entered into the cell cycle [3–5,11–31]. Indeed, the successful
duplication of DNA [32] indicates that such neurons success-
fully complete S phase and precludes the possibility that the re-
expression of various cell cycle markers is an epiphenomena of
reduced proteosomal activity.
To directly test the effect of neuronal cell cycle re-entry on
the initiation of the neuronal alterations observed in AD, we
infected primary cortical neurons in vitro with a combination
of c-myc and ras oncogenes to force non-dividing neurons
into the cell division cycle. Our observations from this
previously unreported methodology support a model of onco-
468 A. McShea et al. / Biochimica et Biophysica Acta 1772 (2007) 467–472genic transformation as an early event in the development of
AD.
2. Materials and methods
2.1. Cell culture
Primary cortical neurons were prepared from Sprague–Dawley rat
embryos at 17–19 days gestation as described [33]. Briefly, cerebral
neocortices were removed and minced in dissociation buffer, treated with
trypsin and dissociated by trituration in DNase and trypsin inhibitor. Cells
were plated at a concentration of 2×105 cells/ml on poly-D-lysine-coated
slide chambers or 0.9×106 cells/ml on poly-D-lysine coated 10 cm tissue
culture plates and infected with the appropriate adenoviral vectors 5 days
after plating. Under these conditions, uninfected cultures are viable for
2–3 weeks.
2.2. Adenoviral gene transduction
Recombinant adenoviruses expressing green fluorescent protein (GFP), c-
myc or ras (H-RAS61L) were constructed and provided by Joseph Nevins at
Duke University [34]. Virus stocks were amplified in HEK 293 cells and
purified by CsCl banding. Each virus is used as follows: GFP, 5×1010 pfu/ml;
Ras 1.25×109 pfu/ml; Myc 4×1010 pfu/ml. Rat embryonic cortical neuronsFig. 1. Cell cycle re-entry in ras/myc adenoviruses infected primary cortical neuron
control GFP or ras/myc containing adenoviruses. Quantification (B) shows a significa
infected cells. Cyclin B1 (red) is only expressed in ras/myc-infected cells (C) along
DAPI (blue).were infected at a multiplicity of infections (MOI) of 50 pfu/cell, and no
cytotoxicity was observed at this MOI.
2.3. Immunocytochemistry
Cells were fixed in 1% paraformaldehyde in phosphate-buffered saline (PBS)
for 30 min and permeabilized with 0.5% NP-40 for 5 min at room temperature,
washed with PBS, then blocked with 5% non-fat milk in PBS for 1 h. Antibodies
were incubated in 1% non-fat milk in PBS overnight at 4 °C. Secondary
antibodies were incubated for 40 min at room temperature, washed three times in
1% non-fat milk in PBS and samples counterstained with DAPI (1 μg/ml in
methanol for 15 min at 37 °C) to localize all nuclei before mounting in Vector
shield (Vector Laboratories, Burlingame, CA). Samples were analyzed under epi-
fluorescence on a Nikon Inverted microscope with Infinity optics and images
capturedwithMetamorph software (Meridian Instruments, Kent,WA). Omission
of primary antibodies showed no positive fluorescent signals.
2.4. Antibodies
Hybridoma supernatants of TG3 and Alz50 antibodies (gift of Peter Davies)
were used at 1:50 and 1:20 respectively. The TG3 monoclonal antibody was
raised against purified PHF's [3] and recognizes tau phosphorylated at Thr 231.
Alz50 was raised against AD brain homogenates [35] and recognizes a
conformational epitope requiring both N terminal residues (7–9) and residuess. (A) BrdU incorporation (red) in primary cortical neurons infected with either
nt increase in BrdU incorporation in ras/myc-infected cells (p<0.001) over GFP-
with a significant concomitant increase in DNA (p<0.001) (D), visualized with
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Santa Cruz, CA, 1:500) is a rabbit polyclonal raised against full-length
recombinant cyclin B. Fluorescent secondary reagents used were goat anti-
mouse CY3 or goat anti-rabbit FITC at dilution of 1:500 (Jackson Laboratories,
West Grove, PA). Isotype specific biotin-conjugated and anti-streptavidin FITC/
CY3 (Southern Biotech, Birmingham, AL) were also used.
2.5. DNA measurements
DNA content was measured following counterstaining fixed samples with
DAPI. DNA replication was quantified by labeling primary neuronal cultures
with 10 μM bromodeoxyuridine (BrdU) coincident with viral infection. Nuclear
BrdU accumulation was assayed by in situ immunofluorescence with an anti-
BrdU monoclonal antibody [37] (Becton Dickinson, San Jose, CA). DNA
content (mean intensity) and BrdU incorporation (% positive cells) measure-
ments were carried out by measuring 5 random fields using Metamorph Image
Analysis Software (Meridian Instruments, Kent, WA). All experiments were
performed at least in triplicate and data presented is the mean of all experiments.
The student's t test was used to determine significance.3. Results
3.1. Cell cycle entry
Cultured primary rat cortical neurons (E18) were infected
with adenovirus vectors encoding two different oncogenes, myc
and a mutationally active ras (H-RAS61L), in an attempt to
force the post-mitotic neurons into the cell cycle. Primary
cortical neurons were infected 5 days after plating and fixed for
immunostaining after either 2 or 5 days.
To determine if cells had re-entered the cell division cycle and
initiated DNA replication (i.e., entered S-phase), cultured neu-
rons infected with GFP or ras/myc were incubated with BrdU
and immunolabeled with anti-BrdU antibody (Fig. 1A). Levels
of BrdU incorporation in approximately 30 and 40% of cells
expressing myc/ras were significantly elevated (Fig. 1B,
p<0.001) compared to cells expressing GFP, suggesting that
infected neurons synthesize DNA and re-enter into the cell cycle.
A mean incorporation frequency (background) of about 10%Fig. 2. Increased phospho-tau expression in ras/myc adenoviruses-infected primary c
cell infected with ras/myc (B) and not in GFP-infected cells (A) after 2 days post-i
correlation with TG3 epitope expression (p<0.00001) (C).(Fig. 1B) in GFP control infected cultures was consistent with
the post-mitotic neuronal population representing >90% of the
culture [38]. To further characterize this cell cycle-related
phenomena, we localized cyclin B1, a cell-cycle marker
specifically induced in the late S/G2 phase of the cell cycle but
not associated with cells in the G1 phase of the cell cycle, and
found increased cyclin B1 in ras/myc adenovirus infected
neurons (Fig. 1C).
To examine if the oncogenically-infected neurons had
become mitotically active (i.e., entered M-phase), the neurons
were counterstained with DAPI to identify mitotic figures and
no mitotic figures were found (Fig. 1C). Therefore, while the
BrdU data (Fig. 1A) indicates progression into S-phase, nuclear
morphology (Fig. 1C) indicates that the mitotic index was not
increased in oncogene-infected neurons.
These data suggest that infected neurons arrest at the begin-
ning of mitosis but fail to complete DNA synthesis and progress
to cell division. Such a notion is consistent with the significant
increase in DAPI labeling of nuclei (p<0.001) (Fig. 1D) and
absence of mitotic figures. Nuclear translocation of cyclin B1 is
typically the mechanism by which mitosis is initiated and
cytoplasmic cyclin B1 expression is associated with cells in the
G2 phase of the cell cycle or cells that are arrested at the earliest
stages of the G2/M checkpoint. Therefore, our data suggest that
primary neurons that are forced to re-enter the cell cycle do not
overcome the G2/M check point and therefore do not progress to
M phase (i.e., analogous to findings in AD) [32].
3.2. Tau expression
To examine whether ras/myc adenoviruses-induced cell
cycle re-entry of neurons was associated with AD-like tau
changes, we used two different antibodies that detect abnorm-
alities in tau: tau phosphorylation (phospho-threonine 231;TG3
antibody) and tau conformational changes (Alz50 antibody).
On average, 30±7.4% of the ras/myc adenovirus infected
neurons (Fig. 2B), but not GFP infected controls (Fig. 2A)ortical neurons. Phospho-tau, detected with antibody TG3 (red), is expressed in
nfection. DNA content visualized with DAPI (blue) shows significant positive
Fig. 3. Conformational change of tau protein by ras/myc adenoviruses infection
in primary cortical neurons. Alz50 antibody staining (red) in primary cortical
neurons infected with either control GFP (green) adenovirus (A) or ras/myc (B)
for 5 days and stained with DAPI (blue). There is over an 8-fold increase of
Alz50 epitope expression from day 2 to day 5 (C).
Fig. 4. Schematic representation of possible stages of the cell cycle and tau
expression. Cell cycle re-entry (i.e., G0 to G1/S and beyond) is associated with
tau phosphorylation and oxidative stress. Unable to enter mitosis, cells enter
“phase stasis” and further conformational changes in tau result.
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noreactivity directly correlated with DNA content determined
using DAPI (p<0.00001) (Fig. 2C).
Alz50 is an antibody that is considered an early pathological
marker for AD [35] and, in contrast to TG3, recognizes a
higher order conformational epitope of tau [36,39]. Less then
1% of cells were positive for Alz50 in the cultures infected with
GFP adenovirus at either 2 days or 5 days post-infection (Fig.
3A). In marked contrast, in ras/myc-infected cells, 5% of
neurons were found to be Alz-50 positive at 2 days post-
infection (data not shown), but, by 5 days, around 50% become
positive (Fig. 3B, C) and there was an 8-fold increase in
immunoreactivity.In summary, the coincidence of the cell cycle markers (BrdU
and cyclin B1) and the appearance of key AD specific PHF
antigens (TG3, Alz50) suggest that the introduction of ras/myc
oncogenes into cultured neurons leads to changes in cell cycle
dynamics and specific elements of AD neuropathology.
4. Discussion
In this study, we have driven non-dividing, differentiated
primary neurons into the cell cycle using adenovirus vectors
carrying two powerful oncogenes, c-myc and a mutationally
active ras (H-RAS61L). Expression of these oncogenes has
been shown to cause fibroblasts to exit G0, overcome the G1/S
checkpoint and re-enter the cell cycle [34]. It was expected that
this stimulus would cause an aberrant cell cycle response in the
neurons and our data suggests that the oncogene-expressing
neurons re-enter the cell cycle and arrest at the G2/M phase of
the cell cycle as determined by the appearance of cyclin B1 and
increased DNA replication (BrdU and DAPI). Notably,
although the BrdU data suggests progression into S-phase in
oncogene-infected neurons, nuclear morphology indicates that
the mitotic index was not increased. Therefore, although
neurons initiate DNA synthesis, they do not appear to complete
mitosis (i.e., divide) consistent with our previous notion of cell
cycle dysfunction [40]. Indeed, the neurons do not show any
progression from the G2/M phenotype and prolonged culture
(>5 days post infection) leads to a steady decrease in the overall
DNA content and DNA condensation consistent with cell death.
The TG3 phosphoepitope of tau is present in both mitotic
cells at G2/M and NFT in AD [3,41] and other neurodegenera-
tive disorders [42]. In mitotic cells, the TG3 phosphoepitope
appears just prior to the onset of prophase and is maximal
during metaphase [3,41]. In AD, the TG3 epitope is observed in
vulnerable neurons prior to NFT formation [14]. In this report,
we show that myc/ras stimulation of neuronal cultures leads to
the appearance of the TG3 epitope. Of note is the observation
that TG3-positive staining precedes Alz50 staining by at least
24 h. This is not unexpected and recapitulates the temporal
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suggests that formation of the Alz50 epitope, which is created
by the association of two distinct regions of the tau molecule, is
more complex than initiation of a mitotic event and may require
secondary events [30], i.e., oxidative stress. Indeed, previous
studies have shown that the Alz50 epitope can be created by
reactive oxidative intermediates produced during neuronal
oxidative stress, coincident with the induction of heme-
oxygenase-1, and that the Alz50 conformation may result
from oxidative damage to an already phosphorylated form of
tau [44].
Although various mitotic markers are upregulated in the
vulnerable neurons in AD brain, no evidence of actual mitosis
has ever been found, suggesting that oncogenically-infected
neurons become arrested at a point(s) prior to the actual event of
cellular division. However, it is well known that once cyclin A
is expressed, the arrested cells lack the ability to return to G0 and
therefore must either complete the cycle or die. Given the lack
of evidence for successful completion of the cell cycle, it is
likely that the re-activation of cell cycle machinery in post-
mitotic neurons leads to their death. In support of this, when a
powerful oncogene, SV40 Tantigen, is expressed specifically in
maturing Purkinje cells in transgenic mice, the cells replicate
their DNA (i.e., initiate cell cycle) but then subsequently
degenerate and die [45]. Similarly, the expression of SV40 T
antigen by the rhodopsin promoter causes photoreceptor
degeneration, again associated with cell cycle reactivation and
DNA synthesis [46].
This report represents the first in vitro model for the
initiation of cell-cycle mediated neurodegeneration that mimics
several features of AD neurodegeneration (Fig. 4). Specifically,
reentry into the cell cycle is associated with DNA replication
and tau phosphorylation/conformational changes. Obviously,
we would anticipate that other approaches to promote cell cycle
re-entry (e.g., SV40T, overexpression of CDK family members
or transcription factors) would induce the same phenotype in
primary neurons. In any case, the availability of the in vitro
oncogenic model presented here will allow us to focus on early
steps leading to neurodegeneration. This, in turn, might allow us
to bring the large arsenal of anti-proliferative compounds
developed over the last decades to bear on the problem of
neurodegeneration [47].
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